Skip to main content

R10933-10987-COV-2066 A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19

NCT04426695

A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19

Associated Conditions

COVID-19

Principal Investigator

Sponsor

Regeneron Pharmaceuticals

COVID-19. The study drug targets the virus that causes COVID-19 and may make it harder for the virus to infect you. The goals of the study include seeing whether the drug can cause serious side effects, whether it lowers infection by the virus, and whether it reduces the need to be in the hospital or the need to have breathing support

This study is currently enrolling.